Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis

<table>Subdivision of DTH positivity (<svg height="8.5" id="M109" style="vertical-align:-0.04095pt" version="1.1" viewbox="0 0 10.1 8.5" width="10.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,-0,0,-.017,.062,8.387)"><path d="M535 230h-212v-233h-58v233h-213v50h213v210h58v-210h212v-50z" id="x2B"></path></g>
</svg>) and negativity (<svg height="4.8874998" id="M110" style="vertical-align:-0.0pt" version="1.1" viewbox="0 0 10.1 4.8874998" width="10.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,-0,0,-.017,.062,4.825)"><path d="M535 230h-483v50h483v-50z" id="x2212"></path></g>
</svg>) to lysate (DTH positivity to KLH is contained in the negative group) grouped on the basis of single response and clinical benefit  (CR+PR+SD).</table>

Journal of Immunology Research

fig5

Figure 5

Figure 5: Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis 

Figure 5 | Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis 